Volume | 1,841,284 |
|
|||||
News | (2) | ||||||
Day High | 1.38 | Low High |
|||||
Day Low | 1.31 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.36 | 1.31 | 1.38 | 1.35 | 1.36 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,091 | 1,841,284 | $ 1.35 | $ 2,483,925 | - | 1.12 - 8.87 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:48:07 | 1 | $ 1.36 | USD |
Esperion Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 127.86M | 94.71M | 93.70M | $ 24.33M | $ -617.96k | -0.79 | -206.91 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 152.46k | 1.00% |
Esperion Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.32 | 1.445 | 1.275 | 1.35 | 1,957,336 | 0.03 | 2.27% |
1 Month | 1.48 | 1.84 | 1.275 | 1.52 | 1,975,339 | -0.13 | -8.78% |
3 Months | 1.49 | 2.16 | 1.12 | 1.57 | 3,727,184 | -0.14 | -9.4% |
6 Months | 6.26 | 7.41 | 1.12 | 3.43 | 3,131,536 | -4.91 | -78.43% |
1 Year | 6.23 | 8.87 | 1.12 | 4.44 | 2,171,109 | -4.88 | -78.33% |
3 Years | 45.89 | 53.73 | 1.12 | 9.92 | 1,389,910 | -44.54 | -97.06% |
5 Years | 37.77 | 79.989 | 1.12 | 17.99 | 1,077,302 | -36.42 | -96.43% |
Esperion Therapeutics Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |